Journey Medical reports record Q1 revenue of $23.3M, up 117% YoY; net loss of $1.4M

Journey Medical Corp

2022-Q1 EPS reported -$0.08 revenue$23,296,000

Record net product revenue $20.8M (+94% YoY); $2.5M milestone from Maruho for QBREXZA Japan approval.
Net loss of $1.4M ($0.08/share) vs net income $0.3M ($0.03) in Q1 2021; adjusted EBITDA $2.3M vs $1.2M.
First patient dosed in Phase 3 trial for DFD-29 for papulopustular rosacea; one additional product launch planned in H2 2022.
Expanded product portfolio with Amzeeq and Zilxi launches; now 9 marketed prescription dermatology products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.